<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p56" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_56{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_56{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_56{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_56{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_56{left:238px;bottom:1061px;letter-spacing:-0.01px;}
#t6_56{left:238px;bottom:1042px;letter-spacing:-0.01px;}
#t7_56{left:238px;bottom:1022px;letter-spacing:-0.01px;}
#t8_56{left:238px;bottom:1003px;letter-spacing:-0.01px;}
#t9_56{left:238px;bottom:983px;letter-spacing:-0.01px;}
#ta_56{left:238px;bottom:964px;letter-spacing:-0.01px;}
#tb_56{left:238px;bottom:944px;letter-spacing:-0.01px;}
#tc_56{left:238px;bottom:925px;letter-spacing:-0.01px;}
#td_56{left:238px;bottom:851px;letter-spacing:-0.01px;}
#te_56{left:238px;bottom:832px;letter-spacing:-0.01px;}
#tf_56{left:238px;bottom:813px;letter-spacing:-0.01px;}
#tg_56{left:238px;bottom:793px;letter-spacing:-0.01px;}
#th_56{left:238px;bottom:774px;letter-spacing:-0.01px;}
#ti_56{left:238px;bottom:754px;letter-spacing:-0.01px;}
#tj_56{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tk_56{left:238px;bottom:661px;letter-spacing:-0.01px;}
#tl_56{left:238px;bottom:642px;letter-spacing:-0.01px;}
#tm_56{left:238px;bottom:588px;letter-spacing:-0.01px;}
#tn_56{left:238px;bottom:568px;letter-spacing:-0.01px;}
#to_56{left:238px;bottom:549px;letter-spacing:-0.01px;}
#tp_56{left:238px;bottom:529px;letter-spacing:-0.01px;}
#tq_56{left:238px;bottom:510px;letter-spacing:-0.01px;}
#tr_56{left:238px;bottom:456px;letter-spacing:-0.01px;}
#ts_56{left:238px;bottom:421px;letter-spacing:-0.01px;}
#tt_56{left:238px;bottom:402px;letter-spacing:-0.01px;}
#tu_56{left:238px;bottom:382px;letter-spacing:-0.01px;}
#tv_56{left:238px;bottom:363px;letter-spacing:-0.01px;}
#tw_56{left:238px;bottom:343px;letter-spacing:-0.01px;}
#tx_56{left:238px;bottom:324px;letter-spacing:-0.01px;}
#ty_56{left:238px;bottom:304px;letter-spacing:-0.01px;}
#tz_56{left:238px;bottom:285px;letter-spacing:-0.01px;}
#t10_56{left:238px;bottom:266px;letter-spacing:-0.01px;}
#t11_56{left:238px;bottom:246px;letter-spacing:-0.01px;}
#t12_56{left:238px;bottom:227px;letter-spacing:-0.01px;}
#t13_56{left:238px;bottom:153px;letter-spacing:-0.01px;}
#t14_56{left:238px;bottom:134px;letter-spacing:-0.01px;}
#t15_56{left:238px;bottom:114px;letter-spacing:-0.01px;}
#t16_56{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_56{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_56{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_56{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts56" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg56Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg56" style="-webkit-user-select: none;"><object width="908" height="1286" data="56/56.svg" type="image/svg+xml" id="pdf56" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_56" class="t s0_56">7.2. Carcinomas in UICC stages I and II: cT1 cN0 and cT2 cN0 </span><span id="t2_56" class="t s1_56">56 </span>
<span id="t3_56" class="t s2_56">However, the difference in survival rates was not statistically significant in a meta- </span>
<span id="t4_56" class="t s2_56">analysis [169]. </span>
<span id="t5_56" class="t s2_56">Canis et al. analyzed 277 patients after transoral surgery for supraglottic carcinomas, 22% of </span>
<span id="t6_56" class="t s2_56">whom received adjuvant radiotherapy. After 5 years, control rates of 85% were achieved for T1 </span>
<span id="t7_56" class="t s2_56">and T2 carcinomas. The 5-year disease-specific and overall survival rates were 92% and 76% in </span>
<span id="t8_56" class="t s2_56">stages I and II and 81% and 59% in stages III and IV [177]. Ambrosch et al. analyzed 48 </span>
<span id="t9_56" class="t s2_56">patients with T1 and T2 supraglottic carcinomas. Here, the five-year rate for local control was </span>
<span id="ta_56" class="t s2_56">92% [178]. An analysis of 303 T1/T2 supraglottic carcinomas treated transorally endoscopically </span>
<span id="tb_56" class="t s2_56">showed a 5-year overall survival of 70%, a disease-specific survival of 82% and a local control of </span>
<span id="tc_56" class="t s2_56">90% [172]. </span>
<span id="td_56" class="t s2_56">In an analysis of transoral laser surgery for T1-T4 supraglottic carcinomas, local control after 2 </span>
<span id="te_56" class="t s2_56">years was 97%, the disease-specific 2-year survival rate was 80%, and overall survival was 85%. </span>
<span id="tf_56" class="t s2_56">Larynx preservation was achieved in 79% [179]. Iro et al. [180] analyzed 141 patients with T1-T4 </span>
<span id="tg_56" class="t s2_56">supraglottic laryngeal carcinomas who were treated by transoral laser surgery and, if </span>
<span id="th_56" class="t s2_56">necessary, neck dissection and adjuvant radiotherapy. Local recurrences occurred in 16% of </span>
<span id="ti_56" class="t s2_56">patients. Recurrence-free survival after 5 years was 65.7%, although this was stage-dependent </span>
<span id="tj_56" class="t s2_56">(stage I: 85.0%; stage II: 62.6%; stage III: 74.2%, and stage IV 45.3%). </span>
<span id="tk_56" class="t s2_56">For disease-specific survival after transoral resection of T1 and T2 vocal cord carcinomas, 5- </span>
<span id="tl_56" class="t s2_56">year survival rates of 89-100% are reported in the literature [6]. </span>
<span id="tm_56" class="t s2_56">In a 2011 meta-analysis on radiotherapy versus laser therapy for T1a glottic carcinoma, 8 </span>
<span id="tn_56" class="t s2_56">observational studies (7 retrospective, 1 prospective) with a total of 1991 patients were </span>
<span id="to_56" class="t s2_56">evaluated with regard to disease-specific survival. There was no statistically significant </span>
<span id="tp_56" class="t s2_56">difference in disease-specific survival; the pooled odds ratio was 1.60 (95% confidence </span>
<span id="tq_56" class="t s2_56">interval 0.79-3.26) in favor of laser surgery [169]. </span>
<span id="tr_56" class="t s2_56">Laryngeal preservation and laryngectomy-free survival </span>
<span id="ts_56" class="t s2_56">Meta-analyses of laryngeal preservation after laser surgery for T1 and T2 vocal cord carcinomas </span>
<span id="tt_56" class="t s2_56">report rates of 83%-100% [181]. A systematic review of mainly comparative retrospective </span>
<span id="tu_56" class="t s2_56">observational studies and cross-sectional studies by Yoo et al. [167] showed a trend towards </span>
<span id="tv_56" class="t s2_56">better laryngeal preservation with initial transoral surgery compared with radiotherapy. In the </span>
<span id="tw_56" class="t s2_56">meta-analysis by Abdurehim et al., data from eight head-to-head observational studies with </span>
<span id="tx_56" class="t s2_56">1175 patients were evaluated for the endpoint: laryngeal preservation [169]. After transoral </span>
<span id="ty_56" class="t s2_56">laser surgery compared with radiotherapy, the larynx was preserved statistically significantly </span>
<span id="tz_56" class="t s2_56">more often (pooled OR=3.11; CI95% [1.1-8.34]). In a meta-analysis of 606 patients with T1 and </span>
<span id="t10_56" class="t s2_56">T2 vocal cord carcinomas from four head-to-head observational studies, no significant </span>
<span id="t11_56" class="t s2_56">difference in laryngectomy-free survival between radiotherapy and transoral laser surgery was </span>
<span id="t12_56" class="t s2_56">shown (OR 0.73, (CI95% [0.39 -1.35])) [168]. </span>
<span id="t13_56" class="t s2_56">In a prospective observational study, Motta et al. reported 5-year recurrence-free overall </span>
<span id="t14_56" class="t s2_56">survival rates for supraglottic T1 tumors of 91% and 82%, and for T2 tumors of 88% and 63%, </span>
<span id="t15_56" class="t s2_56">respectively. Larynx preservation was possible in 87% of T1 </span>
<span id="t16_56" class="t s0_56">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
